Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC).

@article{Cerny1988UnexpectedHT,
  title={Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC).},
  author={Thomas Cerny and Anne Pedrazzini and Rudolf A. Joss and Kurt W. Brunner},
  journal={European journal of cancer & clinical oncology},
  year={1988},
  volume={24 11},
  pages={1791-4}
}
Teniposide (VM 26) as a single agent has shown promising results in the treatment of patients with small cell lung cancer. We treated 32 (30 evaluable) non-pretreated elderly and poor prognosis patients with small cell lung cancer with teniposide 100 mg/day (30 min infusion) days 1-5, every 3-4 weeks. Overall initial performance status was poor (WHO 2 or 3 in 62%). Extensive disease (ED) was documented in 50% including five patients with CNS metastases all of whom received simultaneous cranial… CONTINUE READING